MYC and pancreatic ductal adenocarcinoma: Next, we tested the therapeutic effects of WBC100 on c‐Myc overexpressing pancreatic ductal adenocarcinoma (PDAC), which is a devastating malignancy with almost 90% lethality, emphasizing the need for new therapies, in xenograft mouse models using Mia‐paca2 cells with a high level of c‐Myc protein (Figure 6A).